251 related articles for article (PubMed ID: 34109608)
1. Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity.
Lombardi S; Aaen KH; Nilsen J; Ferrarese M; Gjølberg TT; Bernardi F; Pinotti M; Andersen JT; Branchini A
Br J Haematol; 2021 Jul; 194(2):453-462. PubMed ID: 34109608
[TBL] [Abstract][Full Text] [Related]
2. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
[TBL] [Abstract][Full Text] [Related]
3. The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies.
Ferrarese M; Pignani S; Lombardi S; Balestra D; Bernardi F; Pinotti M; Branchini A
Thromb Res; 2019 Jan; 173():4-11. PubMed ID: 30453126
[TBL] [Abstract][Full Text] [Related]
4. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Nolte MW; Nichols TC; Mueller-Cohrs J; Merricks EP; Pragst I; Zollner S; Dickneite G
J Thromb Haemost; 2012 Aug; 10(8):1591-9. PubMed ID: 22726310
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Kao CY; Yang SJ; Tao MH; Jeng YM; Yu IS; Lin SW
Thromb Haemost; 2013 Aug; 110(2):244-56. PubMed ID: 23676890
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
[TBL] [Abstract][Full Text] [Related]
7. Prolonged activity of factor IX as a monomeric Fc fusion protein.
Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
[TBL] [Abstract][Full Text] [Related]
8. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
[TBL] [Abstract][Full Text] [Related]
9. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
10. Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
Le Quellec S; Enjolras N; Perot E; Girard J; Negrier C; Dargaud Y
Thromb Haemost; 2018 Dec; 118(12):2053-2063. PubMed ID: 30453348
[TBL] [Abstract][Full Text] [Related]
11. Half-life extension through albumin fusion technologies.
Schulte S
Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit.
Desage S; Leuci A; Enjolras N; Holle LA; Singh S; Delavenne X; Wolberg AS; Biswas A; Dargaud Y
Haemophilia; 2023 Nov; 29(6):1483-1489. PubMed ID: 37707428
[TBL] [Abstract][Full Text] [Related]
14. Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.
Xie C; Wang Z; Su Y; Wang J; Shen WC
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861459
[TBL] [Abstract][Full Text] [Related]
15. Treatment of a Hemophilia B Mouse Model with Platelet-Targeted Expression of Factor IX Padua.
Li B; Wu Z; Xu W; Han W; Liu J; Wang D; Zhang G
Hum Gene Ther; 2021 May; 32(9-10):506-516. PubMed ID: 33764159
[TBL] [Abstract][Full Text] [Related]
16. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
17. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
[TBL] [Abstract][Full Text] [Related]
18. Production of biologically active human factor IX-Fc fusion protein in the milk of transgenic mice.
Yan H; Gong X; Xu M; Guo X; Chen Y; Xue Y; Zeng Y; Zeng F
Biotechnol Lett; 2020 May; 42(5):717-726. PubMed ID: 32002712
[TBL] [Abstract][Full Text] [Related]
19. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model.
Cooley B; Broze GJ; Mann DM; Lin FC; Pedersen LG; Stafford DW
Blood; 2019 May; 133(22):2445-2451. PubMed ID: 30992271
[TBL] [Abstract][Full Text] [Related]
20. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.
Samelson-Jones BJ; Finn JD; George LA; Camire RM; Arruda VR
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31219805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
